VERAGENETICS
VERAGENETICSService GroupsPatient VaultLongevity PlannerPersonal Health ManagementPremium ProgramsResidencesOur TeamBlogContact
Clinical Research

Blog & News

The latest scientific articles and news from the world of stem cell applications, genetics, and biotechnology.

PGT-A: Confirm Your Embryos' Chromosomal Integrity Before Transfer
September 21, 2026

PGT-A: Confirm Your Embryos' Chromosomal Integrity Before Transfer

PGT-A (Preimplantation Genetic Testing for Aneuploidy) evaluates the chromosomal integrity of your embryos before transfer, using next-generation sequencing to improve IVF success rates.

Read Article
mRNA Cancer Vaccines and Neoantigens: What Did the KEYNOTE-942 Trial Show in Melanoma?
August 7, 2026

mRNA Cancer Vaccines and Neoantigens: What Did the KEYNOTE-942 Trial Show in Melanoma?

The combination of mRNA-4157/V940 and Keytruda reduced the risk of recurrence in high-risk melanoma in the Phase 2b KEYNOTE-942 trial. Phase 3 process and current status.

Read Article
For Which Types of Cancer Is a Personalized Vaccine Approach Being Evaluated? Mutation Burden Guide
August 5, 2026

For Which Types of Cancer Is a Personalized Vaccine Approach Being Evaluated? Mutation Burden Guide

Tumor mutation burden is associated with immunotherapy response. The scientific rationale for a personalized vaccine approach in cancers such as melanoma, NSCLC, and glioblastoma.

Read Article
FDA-Approved Cancer Vaccine Sipuleucel-T: Dendritic Cell Therapy for Prostate Cancer
August 3, 2026

FDA-Approved Cancer Vaccine Sipuleucel-T: Dendritic Cell Therapy for Prostate Cancer

Sipuleucel-T (Provenge) is the first FDA-approved cellular cancer immunotherapy. Dendritic cell technology, the IMPACT study, and its use in prostate cancer.

Read Article
What Is a Personalized Cancer Vaccine? Tumor Lysate, Dendritic Cells, and the mRNA Approach
July 31, 2026

What Is a Personalized Cancer Vaccine? Tumor Lysate, Dendritic Cells, and the mRNA Approach

Personalized cancer vaccines combine tumor lysate, dendritic cell, and mRNA neoantigen technologies. Their scientific basis and current status of clinical trials.

Read Article
DCVax-L and Dendritic Cell Vaccine for Glioblastoma: Phase 3 Data and Approval Status
July 29, 2026

DCVax-L and Dendritic Cell Vaccine for Glioblastoma: Phase 3 Data and Approval Status

DCVax-L is a dendritic cell + tumor lysate vaccine being studied in patients with glioblastoma. Phase 3 results, survival data, and current FDA/MHRA approval status

Read Article
VERA|GENETICS

Personalized health approaches guided by genetic, biological, and clinical data.

Global Coordinates

+90 542 659 85 70
info@veradoctors.com

Clinical processes are conducted in accordance with relevant health authorities and applicable health standards.

© 2026 Vera Genetics Longevity Group. All academic & clinical credentials fully registered under Turkish Ministry of Health standards.